{"id":793,"date":"2012-12-08T09:01:26","date_gmt":"2012-12-08T09:01:26","guid":{"rendered":"https:\/\/asfema.org\/blog\/?p=793"},"modified":"2017-05-14T12:55:24","modified_gmt":"2017-05-14T12:55:24","slug":"primeros-testimonios-de-los-resultados-de-la-pegpal-con-personas","status":"publish","type":"post","link":"https:\/\/asfema.org\/blog\/index.php\/primeros-testimonios-de-los-resultados-de-la-pegpal-con-personas\/","title":{"rendered":"Primeros testimonios de los resultados de la PegPAL con personas"},"content":{"rendered":"
\"PegPAL\"
Van saliendo los primeros testimonios sobre la PegPAL<\/figcaption><\/figure>\n

Hace ya alg\u00fan tiempo os comentamos c\u00f3mo est\u00e1n los avances sobre la investigaci\u00f3n en PKU<\/strong> (fenilcetonuria)<\/a>. Entre ellos, el m\u00e1s prometedor era con diferencia la PegPAL<\/strong>. Os recordamos que se trata de un medicamento que, a diferencia de la Kuvan<\/strong>, podr\u00eda funcionar en cualquier afectado.<\/p>\n

La PegPAL, como cualquier otro medicamento est\u00e1 sujeto a unos controles muy estrictos antes de pasar a comercializarse y ahora mismo est\u00e1 en fase de pruebas con personas. La \u00faltima antes de poder usarla. Pues bien, hace poco, en el grupo mundial de PKU de Facebook<\/a>, una chica Megan Rockwell<\/strong>, ha compartido su experiencia:<\/p>\n

<\/p>\n

“i was wanted to tell everyone about the PegPal Trial. I am not sure if you have heard of it, but it is a medication\/drug that lowers your PHE levels. I am 20 years old, living right out side of New York City. Every since middle school i have had levels of 25+. Now, thanks to this new medication introduced to our community, my levels are now at a 5, and i am eating dairy, meat, eggs, peanut butter, anything you could think of really. The way that the drug is giving in through a shot injected into a layer of fat in your body. I take mine in my stomach. I take 4 shots, 3 times a week. It way seem like a lot, but the rewards are greater than i could even imagine. PLEASEEEE, message me if you have any questions at all about the trial, the drug its self, or to see if there is a trial starting at a hopsital near you! I am currently participating in the study Mount Sinai Hospital in NYC. I also have a very close friend, Mary Caite, who i am sure would also me open to answering any questions that any of you have!!<\/p>\n

thans guys! hope to hear from of you soon! feel free to friend me also!!”<\/p><\/blockquote>\n

Nos cuenta que tiene 20 a\u00f1os y que est\u00e1 comiendo huevos, carne, l\u00e1cteos. El medicamento se lo tiene que inyectar 4 veces por d\u00eda, 3 d\u00edas a la semana. La prueba la est\u00e1 haciendo en el Hospital Monte Sina\u00ed de Nueva York, y nos pide que hagamos cualquier pregunta.<\/p>\n

Por cierto, que en este otro foro, Mary Caite<\/a>, tambi\u00e9n nos cuenta que le est\u00e1 yendo muy bien.<\/p>\n

Inyectarse puede parecer un incordio, pero hay que tener en cuenta los beneficios que tiene una dieta normal, respecto a cualquier posible carencia de nutrientes.<\/p>\n

Por supuesto, tendremos que estar atentos a c\u00f3mo evoluciona este asunto, y ver qu\u00e9 posibilidades hay de que este estudio se haga tambi\u00e9n en Espa\u00f1a.<\/p>\n

Si las dej\u00e1is en los comentarios preguntas, se las puedo enviar a Megan.<\/p>\n","protected":false},"excerpt":{"rendered":"

Hace ya alg\u00fan tiempo os comentamos c\u00f3mo est\u00e1n los avances sobre la investigaci\u00f3n en PKU (fenilcetonuria). Entre ellos, el m\u00e1s prometedor era con diferencia la PegPAL. Os recordamos que se trata de un medicamento que, a diferencia de la Kuvan, podr\u00eda funcionar en cualquier afectado. La PegPAL, como cualquier otro medicamento est\u00e1 sujeto a unos …<\/p>\n

Primeros testimonios de los resultados de la PegPAL con personas<\/span> Read More »<\/a><\/p>\n","protected":false},"author":1,"featured_media":3234,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":""},"categories":[4],"tags":[113,14,93],"acf":[],"_links":{"self":[{"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/posts\/793"}],"collection":[{"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/comments?post=793"}],"version-history":[{"count":1,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/posts\/793\/revisions"}],"predecessor-version":[{"id":3236,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/posts\/793\/revisions\/3236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/media\/3234"}],"wp:attachment":[{"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/media?parent=793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/categories?post=793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asfema.org\/blog\/index.php\/wp-json\/wp\/v2\/tags?post=793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}